CommercialCoverageMedium impact
08.01.43q, Chimeric Antigen Receptor (CART) Therapy: Yescarta Tecartus, Breyanzi, Kymriah and Aucatzyl
Independence Blue Cross·Oncology, Hematology·Medical Policy
Effective date
Feb 9, 2026
We identified it
Jun 19, 2026
Summary
Updated medical policy for Chimeric Antigen Receptor (CART) Therapy including Yescarta, Tecartus, Breyanzi, Kymriah and Aucatzyl with changes to medical necessity criteria, medical coding requirements, and general guidelines. This affects specialized cancer treatment therapies typically administered in hospital or specialized oncology settings.
Action Required
Before February 9, 2026: Billing and clinical teams must review updated medical necessity criteria for CART therapy procedures. Update prior authorization protocols and documentation requirements for Yescarta, Tecartus, Breyanzi, Kymriah and Aucatzyl treatments. Verify coding guidelines are current in billing system for these specialized cancer therapies.